SXTP - 60 Degrees Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

SXTP

60 DEGREES PHARMACEUTICALS, INC.

NASDAQ

$1.03

▼ DOWN 2.83% (-0.03)

KEY STATISTICS

Market Cap$830.75 K

52w High$8.62

52w Low$1.01

Dividend Yield—

Frequency—

P/E-0.15

Volume22.17K

Shares Out.806.55K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Geoffrey Stuart Dow

COMPENSATION 2026

Salary$228,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$323,425

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 12, 2023

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$285.00K

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-20	Reverse	1:4
2025-02-24	Reverse	1:5
2024-08-12	Reverse	1:12

PRICE

$1.03 ▼ DOWN 2.83% (−$0.03)

OVERLAYS

About 60 Degrees Pharmaceuticals, Inc.

https://www.60degreespharma.com ↗

60 Degrees Pharmaceuticals develops and commercializes therapies for infectious diseases, including Arakoda for malaria, and is advancing Tafenoquine and Celgosivir for COVID-19, babesiosis, Zika, and other viral diseases.

INDUSTRY

Biotechnology

A PRODUCT 60 DEGREES PHARMACEUTICALS, INC. IS KNOWN FOR

ARAKODA® (tafenoquine)

ARAKODA® is an FDA-approved, once-weekly oral medication for malaria prevention in adults, protecting against blood and liver stages, with 60 Degrees Pharmaceuticals expanding efforts to improve accessibility and affordability.